Treatment of amm
OwnerFrank Gilesinventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method of treating a warm-blooded animal, especially a human, having agnogenic myeloid metaplasia (AMM), especially agnogenic myeloid metaplasia which is resistant to conventional chemotherapy.
Claims14
A method of treating agnogenic myeloid metaplasia comprising administering a therapeutically effective amount of a 4-pyridylmethyl-phthalazine derivative to a warm-blooded animal in need thereof.
A combination comprising a 4-pyridylmethyl-phthalazine derivative and at least one compound selected from the group consisting of an androgen, prednisone and hydroxyurea, in which the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier, for simultaneous, separate or sequential use.
A commercial package comprising a 4-pyridylmethyl-phthalazine derivative and at least one compound selected from the group consisting of an androgen, prednisone and hydroxyurea together with instructions for simultaneous, separate or sequential use thereof in the treatment of agnogenic myeloid metaplasia.
Use of a 4-pyridylmethyl-phthalazine derivative of formula I
- wherein
- r is 0 to 2,
- n is 0 to 2,
- m is 0 to 4,
- R1 and R2 (i) are lower alkyl or
- (ii) together form a bridge in subformula I*
- the binding being achieved via the two terminal carbon atoms, or
- (iii) together form a bridge in subformula I**
- wherein one or two of the ring members T1, T2, T3 and T4 are nitrogen, and the others are in each case CH, and the binding is achieved via T1 and T4;
- A, B, D, and E are, independently of one another, N or CH, with the stipulation that not more than 2 of these radicals are N;
- G is lower alkylene, lower alkylene substituted by acyloxy or hydroxy, —CH2—O—, —CH2—S—, —CH2—NH—, oxa (—O—), thia (—S—), or imino (—NH—);
- Q is lower alkyl;
- R is H or lower alkyl;
- X is imino, oxa, or thia;
- Y is unsubstituted or substituted aryl, pyridyl, or unsubstituted or substituted cycloalkyl;
- and
- Z is amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherified or esterified hydroxy, nitro, cyano, carboxy, esterified carboxy, alkanoyl, carbamoyl, N-mono- or N,N-disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower alkylthio, alkylphenylthio, phenylsulfonyl, phenyl-lower alkylsulfinyl or alkylphenylsulfinyl, substituents Z being the same or different from one another if more than 1 radical Z is present;
- and wherein the bonds characterized, if present, by a wavy line are either single or double bonds;
- or an N-oxide of the defined compound, wherein 1 or more N atoms carry an oxygen atom,
- or the salt of such compound having at least one salt-forming group,
- optionally in combination with at least one compound selected from the group consisting of of an androgen, prednisone and hydroxyurea, in which the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier for the manufacture of a medicament for the treatment of AMM.
Dependencies are inferred from the claim text.